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bstract
We conducted a study to assess the feasibility and the potential vaccine coverage of a mass vaccination campaign using a two-dose oral
holera vaccine in an urban endemic neighbourhood of Beira, Mozambique. The campaign was conducted from December 2003 to January
004. Overall 98,152 doses were administered, and vaccine coverage of the target population was 58.6% and 53.6% for the first and second
ounds, respectively. The direct cost of the campaign, which excludes the price of the vaccine, amounted to slightly over $90,000, resulting
n the cost per fully vaccinated person of $2.09, which is relatively high. However, in endemic settings where outbreaks are likely to occur,
ntegrating cholera vaccination into the routine activities of the public health system could reduce such costs.
2005 Elsevier Ltd. All rights reserved.
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. Introduction
Considerable progress has been made during the last two
ecades in the development of new-generation oral vaccines
 This work was supported by Me´decins Sans Frontie`res, the Bill and
elinda Gates Foundation through the Diseases of Most Impoverished
rogram administered by the International Vaccine Institute, Korea, the
overnment of Mozambique, and the World Health Organization. SBL
accine AB, Sweden, donated the vaccines.
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rance. Tel.: +33 140 21 28 48; fax: +33 140 21 28 03.
E-mail address: philippe.cavailler@epicentre.msf.org (P. Cavailler).
against cholera [1]. These are licensed in many countries and
used mainly by travellers from industrialized countries visit-
ing endemic areas. Oral cholera vaccination may complement
usually recommended control measures in areas with high
endemicity. However, a recent WHO meeting of experts rec-
ommended that demonstration projects be first undertaken
[2]. Indeed, demonstration projects using oral cholera vac-
cines are essential to determine whether and under which
circumstances cholera vaccination may help countries in
their fight against the disease. Although Sub-Saharan African
countries account for a significant proportion of the cholera
cases reported worldwide [1]. Feasibility and cost of a mass
264-410X/$ – see front matter © 2005 Elsevier Ltd. All rights reserved.
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oral cholera vaccination campaign have not been explored in
the region, apart from a study undertaken in a refugee setting
in Uganda [3]. Such information will be crucial for informed
decision-making, by governments of cholera-affected coun-
tries and international organizations regarding the utilization
of vaccination for cholera control.
Mozambique experienced major epidemics occurring suc-
cessively from 1997 onwards, and cholera control activi-
ties typically focus on case management, water chlorina-
tion campaigns, and dissemination of hygiene messages.
With improved case management, case fatality ratio have
decreased to below 1%, but remain high in the most severely
affected or isolated areas [4]. In addition, response to cholera
outbreaks is expensive and disrupt other essential health care
activities. Orally administered cholera vaccines represent a
potential new tool to prevent or control cholera outbreaks.
The two-dose oral killed rBS-WC vaccine is well tolerated
and provides significant protection against cholera. Field tri-
als conducted in Bangladesh [5,6] and in Peru [7], showed
that this vaccine confers a high level of protection: 85% after
the second dose and still about 62% protection two years
later, in adult vaccinees. Protection among children less than
5 years is high during the first 6 months and then decreases
dramatically.
A demonstration project, using the two-dose killed oral
cholera vaccine was conducted in Beira, Mozambique. The
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Fig. 1. Map of Mozambique.
and reported annual attack rates of up to 20 cases per 1000
population.
2.2. Vaccine
Each dose of the rBS-WC vaccine (DukoralTM, SBL Vac-
cine AB, Sweden) consists of 1 mg of a recombinant cholera
B subunit, and 2.5 × 1010 of each of the following Vibrio
cholerae O1 strains: Inaba classic, Inaba El Tor and Ogawa
classic [9]. The vaccine was supplied as single dose 3 ml vials.
Since the vaccine is acid labile, each dose was provided with
a sachet of sodium hydrogen carbonate. Buffer solution was
prepared by dissolving the sachet in 150 ml of water. The full
dose of vaccine was mixed with 40, 75 or 150 ml of buffer
solution, for persons 2–4 years, 5–11 years, and over 11 years,
respectively.
Due to the precarious conditions of Beira’s water distri-
bution system, water used for the preparation of the buffer
solution was drawn from the main reservoir of the munic-
ipality and stored in a flexible water tank located near the
vaccine storage facility. The tank was refilled every 4 days
by water trucking. Water temperature and chlorine level were
monitored daily.
2.3. Mass vaccination campaign
gbjectives were: (i) to evaluate the requirements for the orga-
ization of a mass vaccination campaign within an urban
frican setting, the technical difficulties encountered in the
dministration of the vaccine and the costs incurred; (ii) to
ssess the results of this campaign, in terms of acceptabil-
ty and vaccine coverage; and (iii) to assess the effectiveness
f the vaccination. This paper reports on the feasibility, the
cceptability and vaccine coverage only. The results on vac-
ine effectiveness are reported elsewhere [8].
. Materials and method
.1. Study site and population
The port city of Beira, in the Sofala province, is the sec-
nd largest city in Mozambique (Fig. 1). Beira was built
n swampy ground at the mouth of the Pungwe River and
as a population of approximately 450,000, divided into 22
eighbourhoods (bairros). Many areas of Beira are located
elow sea level. Cholera is endemic in Beira with high sea-
onal variations. Cases usually occur during the rainy season
rom January to June. The characteristic marshy areas with
rackish water, periodic flooding during the rainy season,
ommon practice of defecation in open areas, presence of
on-tight latrines, and drainage of municipal waste into the
mbankments perpetuate the risk for cholera [4]. The bairro
f Esturro, a densely populated neighbourhood in the cen-
re of Beira was selected for the demonstration project. It
s facing all the cholera risk factors typical for the areaAlthough residents of Esturro were selected as the tar-
et population, non-Esturro residents requesting vaccination
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were not denied access and were vaccinated as well. A for-
mal census of Esturro residents was conducted in October
2003 and enumerated a total population of 21,818 persons.
All healthy, non-pregnant residents of Esturro who were 2
years of age and older were invited to participate in the mass
vaccination campaign. During the census, 1177 were under
2 years of age and an estimated 5% (1091) were excluded for
potential pregnancy, leaving a target population of 19,550.
One month before the campaign, meetings were organ-
ised to inform community leaders about the vaccine, the
campaign and the feasibility study, obtain their approval,
and solicit their support. Prior to and through-out the mass
vaccination, an information campaign was conducted within
Esturro, using posters and banners, local newspapers, radio
and television. Further, a door-to-door awareness campaign
was conducted during the second vaccination round. The two
doses of vaccine were given at a 14-days interval. The vol-
ume of vaccine ingested by each individual was recorded.
No replacement dose was given unless the content of the cup
was entirely spilt. A vaccination card, issued during the first
round, had to be presented when seeking the second dose of
vaccine.
2.4. Feasibility
All information from the vaccination cards (name, age,
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census data collected from September to October 2003, that
estimated the number of individuals residing in the target area
at 21,818, and included data on age and sex of each household
member, as well as each household address linked to a Geo-
graphic Positioning System (GPS) point. A random sample
of 1084 individuals was selected from the census register.
Households of the selected individuals were located using
GPS.
Cholera vaccination status was ascertained from the vac-
cination card. Vaccine coverage for each vaccination round,
drop-out proportion, and 95% confidence intervals were cal-
culated. Vaccine coverage was also stratified by age and sex.
To evaluate the clinical acceptability of the vaccine, a second
list of 381 individuals over 14 years of age was randomly
selected. Individuals were asked about the taste of vaccine,
the occurrence of side-effects, as well as the possible reasons
for non-vaccination. Data was compiled using Epi-Info 6.04b
[10] and analysed using SPSS 11.5 [11].
2.7. Ethics
The ethical review boards of the International Vaccine
Institute, Seoul, Korea, and of the World Health Organiza-
tion, Geneva, Switzerland approved the study protocol, which
was also presented to the national review board of the Gov-
ernment of Mozambique. Informed consent was obtained at
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rddress, vaccination date, volume ingested) was recorded
n registration sheets and double entered in real time
nto a custom-made entry program using FoxPro software
Microsoft, Seattle, USA). The number of doses delivered
uring each round was also recorded. Vaccine wastage was
stimated by comparing the number of doses delivered with
he number of vials actually used. Time spent on vaccination
as estimated based on the number of doses administered
er outpost per day.
.5. Cost incurred
The following expenses were taken into account for the
nalysis of the cost of the campaign: (i) before the campaign:
ransport of the vaccine from the European producer up to
he field, customs clearance and storage; (ii) during the cam-
aign: supplies and salaries of local personnel. Salaries of
nternational collaborators and expenses related to the feasi-
ility itself (e.g. vaccine coverage survey) were excluded. A
imulation of the cost per fully immunised person was carried
ut using a price per dose of vaccine in the range of US$ 0–3.
he drop-out proportion between the two rounds and the vac-
ine waste observed during the campaign, as well as a 25%
eserve stock, were all taken into account in the simulation.
.6. Vaccine coverage and acceptability
Vaccine coverage and the dop-out proportion between
he two rounds were estimated through a survey conducted
mmediately after the campaign. The sampling frame usedhe community level through meetings with community lead-
rs and at the individual level, by a signature or thumbprint,
ust before vaccine administration.
. Results
.1. Feasibility of the mass vaccination campaign
A total of 115,600 doses of rBS-WC vaccine and the cor-
esponding buffer sachets were packed together resulting in
total volume of 9 m3 and weight of 3310 kg. The vaccine
as transported in EPI cool-boxes by air from Stockholm,
weden to Beira via Nairobi, Kenya. In Beira, vaccines and
uffer were stored between 4 and 8 ◦C in a cold room facil-
ty. EPI cool-boxes were used for daily transportation of the
accine to the vaccination sites.
The two rounds of vaccination were conducted prior to
he start of the 2004 rainy season, during school holidays.
he first round was from 11 to 20 December 2003. The sec-
nd round was from 5 to 12 January 2004. Vaccine outposts
ere set up in churches and schools within Esturro. Each out-
ost was opened daily, from 8 am to 3 pm, 6 days a week,
rom Monday to Saturday. Each outpost had one supervisor
nurse or midwife), and 15–23 team members, depending on
he attendance expected for each site. The teams set-up the
accination site, informed potential vaccinees in the wait-
ng area, prepared the buffer solution, delivered the vaccine,
etched water, cleaned the cups, and filled in the cards and
egistration sheets. In total, 213 persons were involved, with
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Fig. 2. Cholera mass vaccination campaign in the Esturro Neighbourhood, Beira, Mozambique, December 2003 to January 2004.
an average of 21 persons per outpost, and an overall activity
of 4050 person-days. Six vehicles were used for supervision
and to transport staff and supplies to vaccination outposts.
During the first round, 53,836 doses of vaccine were
administered, and 44,316 during the second round, totalling
98,152 doses (Fig. 2). On average, each team was able to
vaccinate 609 persons per day (93 persons per hour). During
the busiest periods, each team was able to vaccinate up to 212
persons per hour. A total of 98,679 doses were used during the
campaign, indicating a vaccine wastage of 527 doses (1%).
Overall 27,500 l of water were used during the two rounds,
representing 280 ml per administered dose.
3.2. Cost incurred
The overall cost of organizing the campaign was $92,287
(Table 1). Of this amount the cost of shipping the vaccine from
Table 1
Cost of mass vaccination campaign with a two-dose oral cholera vaccine
Beira, Mozambique, 2003–2004
Cost ($) Total (%)
Vaccine Free of charge 0.0
Airfreight between Stockholm and Nairobi 6,608 7.2
Regional transport between Nairobi and Beira 28,236 30.6
Insurance fees 900 1.0
Vaccine storage 1,835 1.9
L
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the manufacturer to Beira was evaluated to $34,844 while the
staff salaries accounted for $30,973 (respectively, 37.8 and
33.6% of the total delivery cost). If we assume a reserve
stock of 25% for the vaccine, the amount of vaccine to fully
immunise 44,156 individuals was 123,349 doses. Taking into
account the cost of organizing the campaign, the cost per fully
immunized individual would have ranged from $2.09 for a
free-of-charge vaccine, to $4.88 for a vaccine at $1 per dose,
and to $10.47 if the dose costs $3.
3.3. Vaccine coverage survey and acceptability
The vaccine coverage survey was conducted between 22
January and 7 February 2004. Of the 1084 interviewees, 73
(6.7%) with missing information were excluded from the
Table 2
Vaccine coverage according to vaccination cards, by gender and age. Cholera
mass vaccination campaign in the Esturro Neighbourhood, Beira, Mozam-
bique, 2003–2004
Vaccine coveragea (95% Cl)
First dose Second dose
Gender
Males 56.8 (52.6–61.0) 51.7 (47.4–55.9)
Females 60.9 (56.6–65.1) 55.6 (51.2–59.9)
A
Oocal transportation in Beira 3,439 3.7
accination cards 4,717 5.1
upplies for vaccine administration 8,869 9.6
taff salaries (vaccination campaign) 30,973 33.6
wareness campaign 9,710 10.5
otal 92,287 100.0ge groups
2–4 63.5 (57.9–68.8) 58.7 (52.4–63.6)
5–14 66.1 (61.2–70.7) 62.1 (57.1–66.8)
15 and over 46.1 (41.1–51.1) 40.8 (35.9–45.8)
verall 58.6 (55.6–61.5) 53.6 (50.3–56.3)
a Percentage.
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analysis. Using the vaccination cards for confirmation of the
vaccination status, the first and second dose coverage were
58.6% (95%CI: 55.6–65.1) and 53.6% (95%CI: 50.3–56.3),
respectively (Table 2). The dop-out proportion between the
two rounds was 8.5% (95%CI: 6.4–11.1). Vaccine coverage
did not differ by gender but was significantly lower among
the over-15-year-old as compared to children aged 5–14 (40.8
and 62.1%, respectively, OR = 0.4 [CI = 0.3–0.6]).
Of the 381 individuals who were interviewed for accept-
ability, 190 (49.9%) said they received one or two doses,
while 191 (50.1%) declared they had not received any dose of
the vaccine. Among vaccinated individuals, 13 (7%) thought
that the vaccine had a bad taste, and 184 (96%) reported no
side-effects following its ingestion. Minor and non-specific
complaints, including nausea, abdominal pain or weakness
were reported by six persons. Among the non-vaccinated
individuals, 111 (58%) did not take the vaccine because they
were travelling and 50 (26%) said they were busy. Other rea-
sons being reported: pregnancy (10), refusal (7), long waiting
time (6), taking medication (5).
4. Discussion
This was the first demonstration project aimed at gain-
ing evidence on the use of oral cholera vaccines in an
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much lower than that achieved in previous mass oral cholera
vaccination projects [12,14]. An early challenge in conduct-
ing this campaign was finding a non-refugee setting with
a population size appropriate for the available number of
vaccines. Beira city with its annual occurrence of cholera
and its large outbreak in 1998 was the most suitable for a
mass vaccination campaign. However, in view of the large
population size of the city (500,000) and the limited availabil-
ity of vaccines, and following discussions with community
representatives, a smaller target area was selected within
Beira, taking into account high incidence of cholera in pre-
vious years. However, the exclusion of non-Esturro residents
from vaccinations was not acceptable for the community.
The vaccine was therefore administered to all those who
came to the vaccination outposts on a first-come first-served
basis. As more and more people came from other areas
of Beira, access to vaccine outposts for Esturro residents
became increasingly difficult as the campaign progressed.
The availability of the vaccine for all Beira residents was
therefore a limiting factor in maximizing vaccine coverage in
Esturro.
An important finding from the Esturro survey was the
lower vaccine coverage among adults. An effective approach
for obtaining a more complete coverage in future mass vac-
cination campaigns might require targeting adults through
providing possibilities for vaccination outside working hours
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tndemic setting in Africa. Mass vaccination using the two-
ose oral killed cholera vaccine proved to be feasible in this
ighly cholera-endemic urban area in Mozambique which
equired considerable logistical support and thorough plan-
ing and preparation. However, the size of the target popula-
ion (approximately 20,000), was far short of the actual target
f a real campaign aimed at slopping cholera in Beira city
500,000). Currently, most of the African population lives in
oor suburbs of mega-cities of several million inhabitants.
onsidering cholera control in such needy environments,
ould involve addressing problems on a much larger scale
han the demonstration project in Esturro.
Nearly 100,000 doses of vaccine were administered dur-
ng two rounds of immunization conducted within one
onth. The rate at which the vaccination were given was,
t most, 609 doses per day (93 dose per hour), less than
hat reported during mass vaccination campaign conducted
n Vietnam using a two doses oral cholera vaccine [12],
nd less than that recorded during mass vaccination cam-
aigns using needles (i.e. measles or meningitis), during
hich, an average of 350 individuals were vaccinated per
our [13]. The difference can be attributed to the time needed
o provide information regarding the vaccine, to drink the
accine, especially in younger children and to record the
accination.
Although enhanced by the sound and transparent infor-
ation strategy being adopted and targeting the community
eaders and politicians, as well as the general population
f Beira and Esturro residents, the vaccination campaign
n Beira resulted in a two-dose vaccine coverage of 54%,o increase their participation. When questioned regarding
he reasons for non-participation during the vaccine cover-
ge survey, more than half of the non-vaccinated residents
eclared that they were travelling at the time of the cam-
aign. Trips were related to the Christmas celebrations and
reparation of agricultural areas before the start of the rainy
eason. Although it is important to schedule mass vaccina-
ion activities prior to the cholera season, it is also important
o take into consideration community activities in order to
aximize participation.
The cost of the campaign was relatively high. The project
imed at ensuring an efficient process for the mass vaccina-
ion campaign and vaccination teams were therefore staffed
enerously. Expenses could be reduced through the inte-
ration of cholera vaccination in the public health system
ctivities. In contrast, there were few options for decreasing
he transport costs of the vaccine to the field site. Due to the
isk of breaking the cold chain, an airplane was chartered for
ransporting the vaccines from Nairobi to Beira. Because of
he high volume of storage capacities needed to safely store
he vaccine, the absence of a safe cold chain could jeopar-
ize future mass vaccination campaigns in certain settings.
or this project, the vaccine was provided free of charge.
owever, vaccine and vaccine delivery costs are likely to be
he main constraints to a wider use of cholera vaccination
ampaigns.
This study was, to our knowledge, the first large-scale
roject using the two-dose killed oral cholera vaccine in a
eal life situation. Logistics were challenging partly due to
he fact that the implementation of the campaign needed to
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be documented in order to gain evidence on the use of such
vaccines in an endemic setting. Future mass vaccination
campaigns outside a research setting can be simplified but
will always require thorough planning and preparation. A
key question for public health decision makers is where and
when this vaccine should be used. Given the relatively short
immunological protection and the relatively high cost, it
would currently not be appropriate for routine vaccination
programs in resource poor settings.
Lessons learned on the importance of timing, targeting
adults, and emphasizing the need for two doses will be use-
ful for planning future campaigns using the killed oral cholera
vaccine. Cost of vaccine remains a key issue, especially when
considering large implementation of cholera immunization in
countries where cholera is endemic, while keeping in mind
that the cost of the vaccine is dependent on the quantities
of vaccines produced. Governments and donors should pro-
vide funding for prevention of, and preparedness for cholera
outbreaks.
Pre-emptive vaccinations can not only save costs related to
emergency responses to control outbreaks, but more impor-
tantly prevent unnecessary suffering.
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